JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Scope & Guideline

Empowering researchers and practitioners in clinical oncology.

Introduction

Welcome to your portal for understanding JAPANESE JOURNAL OF CLINICAL ONCOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0368-2811
PublisherOXFORD UNIV PRESS
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1971 to 2024
AbbreviationJPN J CLIN ONCOL / Jpn. J. Clin. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND

Aims and Scopes

The Japanese Journal of Clinical Oncology focuses on advancing the understanding and treatment of cancer through high-quality research and clinical studies. It aims to provide a platform for innovative approaches in oncology, with a strong emphasis on both clinical and translational research.
  1. Clinical Trials and Therapeutics:
    The journal extensively publishes findings from clinical trials, including phase I-III studies, which evaluate new therapeutic approaches and combinations in various cancer types.
  2. Genomic Profiling and Precision Medicine:
    A significant emphasis is placed on genomic profiling and its implications for personalized cancer treatment, highlighting studies that explore molecular characteristics and targeted therapies.
  3. Multidisciplinary Approaches in Oncology:
    The journal promotes the integration of various specialties in cancer treatment, including surgery, radiotherapy, and supportive care, reflecting the complexity of cancer management.
  4. Health Economics and Policy in Cancer Care:
    Research addressing the cost-effectiveness of cancer treatments and the impact of health policies on cancer care in Japan is a core focus, aiming to improve healthcare delivery.
  5. Survivorship and Quality of Life:
    Studies that explore cancer survivorship, quality of life, and supportive care strategies for cancer patients, particularly in the context of the aging population in Japan, are frequently featured.
  6. Emerging Therapies and Technologies:
    The journal highlights innovative therapies, including immunotherapy and novel drug delivery systems, and their clinical implications, showcasing the evolving landscape of cancer treatment.
The Japanese Journal of Clinical Oncology has been adapting to the rapidly evolving landscape of cancer research. This section identifies the emerging trends and themes that have gained traction in recent publications, signaling areas of increased interest and research activity.
  1. Immunotherapy and Checkpoint Inhibitors:
    There is a growing emphasis on studies exploring the efficacy and safety of immunotherapy, particularly immune checkpoint inhibitors, as they have revolutionized cancer treatment.
  2. Real-world Evidence and Outcomes:
    The journal is increasingly publishing studies that focus on real-world evidence, assessing the effectiveness and safety of cancer treatments in everyday clinical settings, which is crucial for understanding treatment impacts beyond clinical trials.
  3. Multi-Omics Approaches:
    Research utilizing multi-omics technologies, integrating genomics, proteomics, and metabolomics, is on the rise, reflecting a trend towards comprehensive patient profiling to inform treatment decisions.
  4. Health Inequities and Access to Care:
    Emerging themes include the exploration of health disparities in cancer care, addressing how socioeconomic factors affect access to treatment and outcomes, particularly in the context of Japan's diverse population.
  5. Patient-Reported Outcomes and Quality of Life:
    There is a notable increase in studies focusing on patient-reported outcomes and quality of life assessments, highlighting the importance of patient perspectives in oncology research.

Declining or Waning

While the Japanese Journal of Clinical Oncology continues to thrive in many areas, certain themes have seen a decline in recent years. This section explores those waning scopes, indicating shifts in research focus or decreasing publication frequency.
  1. Traditional Chemotherapy Studies:
    With the advent of targeted therapies and immunotherapy, the focus on traditional chemotherapy regimens has diminished, reflecting a broader shift towards more innovative treatment modalities.
  2. Single-Institution Studies:
    There has been a noticeable decrease in the publication of studies from single institutions, as the journal increasingly prioritizes multicenter and population-based studies that provide more comprehensive data.
  3. Basic Science Research:
    The journal has seen a reduced emphasis on basic science research related to oncology, as it shifts towards clinical application and translational studies that have direct implications for patient care.
  4. Palliative Care Research:
    Although still important, research focusing solely on palliative care without integration into broader oncological treatment strategies has become less prominent, as the journal seeks to publish studies that combine palliative and curative approaches.
  5. Epidemiological Studies:
    The frequency of publishing epidemiological studies on cancer incidence and prevalence has decreased, possibly due to a greater focus on intervention-based research and clinical outcomes.

Similar Journals

Translational Lung Cancer Research

Unlocking innovative solutions for lung cancer management.
Publisher: AME PUBLISHING COMPANYISSN: 2218-6751Frequency: 6 issues/year

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

Onkologie

Advancing the Frontiers of Oncology and Hematology.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

ESMO Open

Fostering global collaboration in oncology research.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

Nature Reviews Clinical Oncology

Unlocking Innovations in Oncology Research
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Therapeutic Advances in Medical Oncology

Fostering innovation in cancer therapies worldwide.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

Translational Oncology

Pioneering the Next Generation of Cancer Treatments
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

International Cancer Conference Journal

Unveiling Breakthroughs in Oncology Research
Publisher: SPRINGER INT PUBL AGISSN: 2192-3183Frequency: 4 issues/year

International Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.

Gaceta Mexicana de Oncologia

Connecting Researchers to Combat Cancer Together.
Publisher: SOC MEXICANA ONCOLOGIA, A CISSN: 1665-9201Frequency: 6 issues/year

Gaceta Mexicana de Oncologia, published by the SOC MEXICANA ONCOLOGIA, A C, is a prominent Open Access journal that has contributed significantly to the field of oncology since its inception in 2002. With an ISSN of 1665-9201, this journal is dedicated to disseminating high-quality research pertaining to cancer studies, making it an essential resource for researchers, healthcare professionals, and students alike. Operating out of Spain, it serves as a platform for sharing innovative findings and clinical advancements in oncology. The journal's impact in the research community is reflected in its current rankings, placing it in the Q4 category for Cancer Research and Oncology fields. Despite its emerging status within the academic tiers, Gaceta Mexicana de Oncologia aims to enhance its presence in the scholarly domain, especially during its converged years from 2009 to 2024. The accessibility of its articles empowers a wider audience, fostering collaboration and knowledge-sharing necessary for combating cancer in diverse populations.

Current Oncology

Empowering Research, Enriching Lives
Publisher: MDPIISSN: 1198-0052Frequency: 12 issues/year

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

JOURNAL OF CLINICAL ONCOLOGY

Pioneering breakthroughs in oncology and patient care.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0732-183XFrequency: 36 issues/year

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.